Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (ARTL) announced the receipt of Clinical Trials Authorization for its Cancer Appetite Recovery Study (CAReS) of ART27.13 in the UK. This Phase I/II trial targets cancer patients suffering from anorexia, addressing a significant unmet medical need. The company also secured a Mitacs Accelerate grant to further develop its ART26.12 program, exploring its potential in treating anxiety disorders. Financially, ARTL reported a net loss of $1.43 million for Q1 FY2021, with operating expenses slightly rising to $1.44 million.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. EDT and accessible for 90 days. Artelo is focused on developing therapeutics that modulate the endocannabinoid system to address unmet medical needs in conditions such as cancer, PTSD, and pain. The company is based in San Diego and is advancing a portfolio of product candidates aimed at various diseases.
Artelo Biosciences (NASDAQ: ARTL) has filed a composition of matter patent application with the UK Patent Office for a new solid dosage formulation related to its lead clinical program, ART27.13. This formulation aims to treat cancer patients suffering from anorexia. The company has received Clinical Trial Authorization for its Cancer Appetite Recovery Study (CAReS) and plans to begin enrollment by year-end 2020. If allowed, the patent application is expected to secure exclusivity for ART27.13 through 2041.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 13th Annual LD Micro Main Event investor conference on December 15 at 9:40 a.m. PST. Gregory D. Gorgas, President and CEO, will present to a live virtual audience. The conference format includes a 10-minute presentation followed by a Q&A session. The Main Event takes place on December 14-15 on the Sequire Virtual Events platform. Artelo is focused on developing therapeutics targeting the endocannabinoid system, addressing unmet medical needs in various conditions such as cancer and pain.
Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Gregory R. Reyes, M.D., Ph.D., to its Board of Directors, effective November 30, 2020. Dr. Reyes brings over 35 years of experience in biotech and pharmaceuticals, having advanced over 50 drug candidates in his career. He previously held significant positions at Celgene, Biogen Idec, Pfizer, and Schering-Plough, contributing to the development of successful therapeutics like Merck’s Victrelis. Artelo aims to leverage Dr. Reyes' expertise to enhance its clinical development and product pipeline.
Artelo Biosciences (NASDAQ: ARTL) announced a Mitacs Accelerate grant that will fund 50% of research costs for evaluating ART26.12 as a potential treatment for anxiety disorders. The grant supports preclinical research in collaboration with Dr. Steven Laviolette at the University of Western Ontario. ART26.12 aims to inhibit Fatty Acid Binding Protein 5 (FABP5), potentially increasing anandamide levels, which may enhance treatment efficacy for anxiety. The funding will also aid in pharmacology research and biomarker identification related to stress response.
Artelo Biosciences (NASDAQ: ARTL) has received Clinical Trial Authorization (CTA) in the UK for its Cancer Appetite Recovery Study (CAReS) aimed at treating cancer-related anorexia. The Phase 1/2 trial will evaluate the efficacy and safety of synthetic cannabinoid ART27.13, targeting a market of over $2 billion. With a recruitment goal of 43 patients, the company plans to initiate enrollment before year-end 2020, despite operational challenges posed by the Covid-19 pandemic. The trial addresses a significant unmet need, as cancer-related anorexia affects over 60% of advanced cancer patients.
Artelo Biosciences (NASDAQ:ARTL), a biopharmaceutical company, will present at the Virtual Fall Investor Summit from November 16-18, 2020. CEO Gregory D. Gorgas is scheduled to speak on November 18 at 11:30 a.m. ET. The presentation will be available for live streaming and replay. Attendees can schedule one-on-one meetings via video calls during the summit. Artelo focuses on developing therapeutics targeting the endocannabinoid system for conditions like anorexia, cancer, and pain. For details, visit www.artelobio.com.
Artelo Biosciences (NASDAQ: ARTL) recently announced the closing of a $7.6 million underwritten public offering and received ethics approval for the CAReS study of ART27.13 in the UK. The company expanded its exclusive worldwide license with Stony Brook University for the FABP5 inhibitor platform aimed at treating cancer, pain, and inflammation. For the fiscal year ending August 31, 2020, Artelo reported a net loss of $4.65 million or $1.26 per share, an increase from the previous year, and had cash reserves of approximately $2.14 million.
Artelo Biosciences (NASDAQ: ARTL) has announced a significant advance in the treatment of psychological disorders, filing a patent for FABP5 inhibitors aimed at conditions like anxiety and PTSD. Recent preclinical data indicate that inhibiting FABP5 increases anandamide levels in critical brain regions, potentially providing a new therapeutic pathway with fewer side effects compared to current treatments. This is particularly relevant as COVID-19 may heighten PTSD risks. The company has also expanded its patent estate by acquiring rights to third-generation FABP5 inhibitors.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
